Sumanta K. Pal/ cityofhope.org
Sep 7, 2025, 15:32
Sumanta Pal: Contribution of IO in TKI/IO Combinations For Non-Clear Cell Kidney Cancer
Sumanta Pal, Professor and Vice Chair of Academic Affairs at City of Hope, shared a post on X:
“Until we have randomized studies, we will not truly understand the contribution of IO in TKI/IO combinations for non-clear cell kidney cancer.
STELLAR304 and SAMETA are v imp P3 trials that have yet to read out – in the meantime, please consider supporting SWOG PAPMET2, led by Benjamin L Maughan.”
More posts featuring Kidney Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 7, 2025, 15:24
Sep 7, 2025, 14:57
Sep 7, 2025, 14:41
Sep 7, 2025, 14:23
Sep 7, 2025, 14:05